Anti‐inflammatory synergy of MEN16132, a kinin B2 receptor antagonist, and dexamethasone in carrageenan‐induced knee joint arthritis in rats
Authors:
- 5 November 2010
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 161 (7) , 1616-1627
Abstract
BACKGROUND AND PURPOSE Bradykinin, through its B2 receptor, is involved in inflammatory processes related to arthropathies. In carrageenan and lipopolysaccharide (LPS)‐induced arthritis in rat, the anti‐inflammatory activity of MEN16132, a potent and selective kinin B2 receptor antagonist, was compared with that of steroidal and nonsteroidal anti‐inflammatory drugs. The interaction between MEN16132 and dexamethasone was also investigated.EXPERIMENTAL APPROACH Drugs, alone or in combination, were injected into the knee joint 30 min before intra‐articular administration of carrageenan or LPS, in pentobarbital anaesthetized rats. Effects on incapacitation, oedema, neutrophil recruitment and kallikrein system activation, in the knee joint, were assessed.KEY RESULTS MEN16132 and dexamethasone (10–300 µg per knee) dose‐dependently reduced carrageenan‐induced joint pain, oedema and neutrophil infiltration, reaching a maximal inhibition of about 50%. Dexketoprofen exerted a similar analgesic activity, whereas it did not affect the other inflammatory responses. MEN16132 showed a partial inhibition of LPS‐induced joint pain, whereas dexamethasone produced a full analgesic effect. Combination of MEN16132 and dexamethasone showed a strong synergistic interaction in inhibiting both carrageenan and LPS‐induced knee joint inflammation. Dexamethasone did not prevent the contact activation of prekallikrein by carrageenan and the subsequent release of kallikreins and bradykinin in the synovium.CONCLUSIONS AND IMPLICATIONS Steroids and kinin B2 receptor antagonists appear to relieve arthritic symptoms induced by carrageenan or LPS and act synergistically to inhibit joint inflammation. This could have interesting therapeutic implications, possibly opening the way for combination therapies in the control of inflammatory arthropathies.Keywords
This publication has 42 references indexed in Scilit:
- Effect of Intra-articular 4-(S)-Amino-5-(4-{4-[2,4-dichloro-3-(2,4-dimethyl-8-quinolyloxymethyl)phenylsulfonamido]-tetrahydro-2H-4-pyranylcarbonyl} piperazino)-5-oxopentyl](trimethyl)ammonium chloride hydrochloride (MEN16132), a Kinin B2 Receptor Antagonist, on Nociceptive Response in Monosodium Iodoacetate-Induced Experimental Osteoarthritis in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Guide to Receptors and Channels (GRAC), 4th editionBritish Journal of Pharmacology, 2009
- Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis II: Mechanistic Pharmacodynamic Model for Dexamethasone Effects in Lewis Rats with Collagen-Induced ArthritisThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Intracellular Signaling in Primary Sensory Neurons and Persistent PainNeurochemical Research, 2008
- Arthritis and pain. Future targets to control osteoarthritis painArthritis Research & Therapy, 2007
- Selective inhibitors of cyclo‐oxygenase‐2 (COX‐2) induce hypoalgesia in a rat paw model of inflammationBritish Journal of Pharmacology, 2002
- Inhibitory effect of annexin I on synovial inflammation in rat adjuvant arthritisArthritis & Rheumatism, 1999
- Bradykinin B1 and B2 receptors, tumour necrosis factor α and inflammatory hyperalgesiaBritish Journal of Pharmacology, 1999
- Effects of an orally active non‐peptide bradykinin B2 receptor antagonist, FR173657, on plasma exudation in rat carrageenin‐induced pleurisyBritish Journal of Pharmacology, 1997
- Inhibition of rats adjuvant arthritis by a bradykinin antagonist hoe 140 and its influence on kallikreinsGeneral Pharmacology: The Vascular System, 1996